<DOC>
	<DOCNO>NCT00002308</DOCNO>
	<brief_summary>To make stavudine ( d4T ) available patient advance HIV disease alternative antiretroviral satisfactory . To study safety efficacy two dose level twice-daily regimen .</brief_summary>
	<brief_title>A Study Stavudine HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV positivity CD4 count &lt; 300 cells/mm3 . Intolerance failure approve antiretroviral therapy . Ability provide inform consent ( parent guardian appropriate ) . NOTE : Incarcerated person may eligible participate . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Grade 2 bad diseaserelated peripheral neuropathy . Unresolved drugrelated peripheral neuropathy severity attributable nucleoside analog ( AZT , ddC , ddI ) . Malignancy likely require systemic chemotherapy myelosuppressive neurotoxic drug first 3 month stavudine treatment . Pregnancy ( physician pregnant patient may contact BristolMyers determine eligibility stavudine therapy another protocol ) . Strongly discourage : AZT , ddI , ddC , antiretroviral agent .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Stavudine</keyword>
</DOC>